Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines

Vaccine

Volumn 17, Issue 19, 1999, Pages 2366-2376

  Guiso, Nicole ^a   Capiau, Carine ^b   Carletti, Georges ^b   Poolman, Jan ^b   Hauser, Pierre ^b  

^a INSTITUT PASTEUR   (France)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Acellular vaccine; Bordetella pertussis; Murine model of protection

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ANIMAL MODEL; ARTICLE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY; IMMUNIZATION; MOUSE; NONHUMAN; PERTUSSIS; PREDICTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0033553597     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00037-7     Document Type: Article

References (31)

1. Greco D., Salmaso S., Mastrantonio P., Giuliano M., Tozzi A.E., Anemona A., Ciofi Degli Atti M.L., Giammanco A., Panei P., Blackwelder W.C., Klein D.L., Wassilak S.G.F. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334:1996;341-348.
2. Gustafsson L., Hallander H.O., Olin P., Reizebstein E., Storsaeter J. A controlled trial of a two component acellular, a five-component acellular and a whole-cell pertussis vaccine. N. Engl. J. Med. 334:1996;349-355.
3. Schmitt H.-J., Wirsing von Konig C.H., Neiss A., Bogaerts H., Bock H.L., Schulte-Wissermann H., Gahr M., Schult R., Folkens J.U., Rauh W., Clemens R. Efficacy of acellular pertussis vaccine in early childhood after household exposure. J.A.M.A. 275:1996;37-41.
4. Simondon F., Preziosi M.P., Yam A., Kane C.T., Chabirand L., Iteman I., Sanden G., Mboup S., Hoffenbach A., Knudsen K., Guiso N., Wassilak S., Cadoz M. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine. 15:1997;1606-1612.
5. Liese J.G., Meschievitz C.K., Harzer E.et al. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr. Infect. Dis. J. 16:1997;1038-1044.
6. Stehr K., Cherry J.D., Heininger U., Schmittgrohe S., Uberall M., Laussucq S., Eckhardt T., Meyer M., Engelhardt R., Christenson P. A comparative efficacy trail in Erlangen, Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine or DT vaccine. Pediatrics. 101:1998;1-11.
7. Storsaeter J., Hallander H.O., Gustafsson L., Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine. 16:1998;1907-1916.
8. Cherry J.D., Gornbein J., Heininger U., Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine. 16:1998;1901-1906.
9. Bordet J., Gengou O. Le microbe de la coqueluche. Ann. Inst. Pasteur. 20:1906;731-741.
10. Kendrick P., Eldering G., Dixon M.K. Mouse protection tests in the study of pertussis vaccine: a comparative series using intracerebral route for challenge. Am. J. Public Health. 37:1947;803-810.
11. Standfast A.F.B. The comparison between field trials and mouse protection tests against intranasal and intracerebral challenges with Bordetella pertussis. Immunology. 2:1958;135-143.
12. Corbel M.J., Xing D.K.L. A consideration of control requirements for acellular pertussis vaccines. Dev. Biol. Stand. 89:1997;343-347.
13. Hall E., Parton R., Wardlaw A.C. Responses to acellular pertussis vaccines and component antigens in a coughing-rat model of pertussis. Vaccine. 16:1998;1595-1603.
14. Khelef N.C., Bachelet C.M., Vargaftig B.B., Guiso N. Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins and toxins. Infect. Immun. 62:1994;2893-2900.
15. Mills K.H.G., Ryan M., Ryan E., Mahon B.P. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66:1998;594-602.
16. Sato Y., Izumiya K., Sato H., Cowell J.L., Manclark C.R. Aerosol infection of mice with Bordetella pertussis. Infect. Immun. 29:1980;261-266.
17. Mills K.H.G., Barnard A., Watkins J., Redhead K. Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect. Immun. 61:1993;399-410.
18. Redhead K., Barnard A., Watkins J., Mills K.H.G. Effective immunisation against Bordetella pertussis respiratory infection in mice is dependent on the induction of cell mediated immunity. Infect. Immun. 61:1993;3190-3198.
19. International requirements for biological substances. Annex 1. Requirements for pertussis vaccine. WHO Tech. Rep. Ser. 274:1964;25-40.
20. Stainer D.W., Scholte M.J. A simple chemically defined medium for the production of Phase I Bordetella pertussis. J. Gen. Microbiol. 63:1971;211-220.
21. Dunnett C.W. A multiple comparisons procedure for comparing several treatments with a control. J.A.S.A. 50:1955;1096-1121.
22. Shapiro S.S., Wilk M.B. An analysis of variance test for normality. Biometrika. 52:1965;591-611.
23. Brown M.B., Forsythe A.B. Robust tests for equality of variances. J.A.S.A. 69:1974;364-367.
24. Olin P., Rasmussen F., Gustafsson L., Hallander H.O., Heijbel H. Randomised controlled trial of two-component, three-component and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet. 350:1997;1569-1577.
25. Sato Y., Sato H. Animal models of pertussis. Wardlaw A.C., Parton R. Pathogenesis and immunity in pertussis. 1988;309-325 J. Wiley & Sons Ltd.
26. Pittman M. Genus Bordetella. Krieg N.R., Holt J.C. Bergey's manual of systematic bacteriology. 1984;388-393.
27. Woods D.E., Franklin R., Cryz S.J., Ganss M., Peppler M., Ewanowich C. Development of a rat model for respiratory infection with Bordetella pertussis. Infect. Immun. 57:1989;1018-1020.
28. Hall E., Parton R., Wardlaw A.C. Differences in coughing and other responses to intrabronchial infection with Bordetella pertussis among strains of rats. Infect. Immun. 65:1997;4711-4717.
29. Barbic J., Leef M.F., Burns D.L., Shahin R.D. Role of gamma interferon in natural clearance of Bordetella pertussis infection. Infect. Immun. 65:1997;4904-4908.
30. Guiso N. Isolation, identification and characterization of Bordetella pertussis. Dev. Biol. Stand. 89:1996;193-198.
31. Mooi F.R., van Oirschot H., Heuvelman K., van der Heide H.G.J., Gaastra W., Willems R.J.L. Polymorphism in the Bordetella pertussis virulence factors P.69/Pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect. Immun. 66:1998;670-675.